Chris Jones has over 30 years of experience taking new medical products from concept through to market adoption in both venture funded and Fortune 500 companies.

He currently works as Chair and Non-Executive Director for a portfolio of life science companies across the UK including Verinnogen (Chair), Brigid Bio (Chair), Carbometrics, MediSieve, Deltex Medical, and Health Enterprise East. As Executive Chair of Mologic he led the company post their spin-out from Alere, closing two institutional venture rounds and managed the successful sale negotiations to Global Access Health in 2021 delivering a 5X exit for investors. He has raised over $50M in funding from Venture, Corporate and Angel investors, closed multiple licensing and partnering deals with large pharma partners and won over £10M in non-dilutive grant funding.

In his current roles, in addition to fundraising, strategy and business development, Chris provides hands on support for business-critical areas that are often under-resourced in early-stage companies including IP strategy, licensing negotiations and commercial planning. From 2008-2015 as CEO of GlySure he led the development of the world's first continuous intravascular glucose sensor from laboratory proof of concept to CE approval. Prior to joining GlySure he was CEO of Tensys Medical developing and commercializing the first continuous, non-invasive blood pressure monitor resulting in the sale of the company in 2008. He also spent nine years with Nellcor Inc, a division of Tyco Healthcare, where he was VP of Marketing responsible for the $700M WW critical care business. Chris is a graduate of Yale University with a Bachelor of Science Degree in Molecular Biophysics and Biochemistry.